Zacks Research Issues Optimistic Forecast for PBH Earnings

Key Points

• Zacks Research has upgraded its Q2 2026 earnings per share estimate for Prestige Consumer Healthcare to $0.99, an increase from the previous estimate of $0.97.
• The company is currently rated as a "Strong Sell" by Zacks, with a consensus price target of $93.33 and mixed ratings from analysts—including three buy ratings and one sell rating.
• Prestige Consumer Healthcare reported a revenue of $249.53 million in its last earnings announcement, which was lower than the expected $260.71 million, reflecting a 6.6% year-over-year decline.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Investment analysts at Zacks Research boosted their Q2 2026 earnings estimates for shares of Prestige Consumer Healthcare in a report issued on Tuesday, September 16th. Zacks Research analyst Team now forecasts that the company will earn $0.99 per share for the quarter, up from their prior estimate of $0.97. Zacks Research has a "Strong Sell" rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q2 2027 earnings at $1.19 EPS, Q4 2027 earnings at $1.27 EPS and Q1 2028 earnings at $1.27 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. During the same quarter in the prior year, the business earned $0.90 EPS. The firm's revenue for the quarter was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a report on Friday, August 8th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Hold" and an average price target of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock traded down $0.99 during mid-day trading on Thursday, hitting $63.11. The company had a trading volume of 1,033,476 shares, compared to its average volume of 567,570. Prestige Consumer Healthcare has a 52-week low of $61.93 and a 52-week high of $90.04. The stock's 50 day moving average price is $69.07 and its 200-day moving average price is $78.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The company has a market capitalization of $3.11 billion, a P/E ratio of 14.81, a P/E/G ratio of 1.99 and a beta of 0.46.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of PBH. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Prestige Consumer Healthcare by 45.3% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock worth $135,903,000 after purchasing an additional 493,199 shares during the last quarter. Geode Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company's stock worth $112,843,000 after acquiring an additional 9,455 shares during the period. Invesco Ltd. raised its stake in Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after acquiring an additional 261,537 shares during the last quarter. Congress Asset Management Co. increased its position in shares of Prestige Consumer Healthcare by 1.8% in the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company's stock valued at $80,616,000 after buying an additional 18,015 shares in the last quarter. Finally, Westwood Holdings Group Inc. raised its position in shares of Prestige Consumer Healthcare by 2.4% during the 2nd quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company's stock valued at $70,420,000 after buying an additional 20,626 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.